advancing cell therapeutic products for clinical use v2.… · advancing cell therapeutic products...
TRANSCRIPT
Proprietary data of Pluristem Therapeutics Inc.
1
Advancing cell therapeutic products for clinical use
Proprietary data of Pluristem Therapeutics Inc.
2
This presentation concerning Pluristem Therapeutics may include forward-looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com
Forward Looking Statement
Proprietary data of Pluristem Therapeutics Inc.
3
• Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local
and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient,
controlled production of multiple cell products in commercial quantities – “the process is the product”
• Active with regulators in the U.S., EU, S. Korea, Australia & Israel
• Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study)
Corporate Overview
Proprietary data of Pluristem Therapeutics Inc.
4
• Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015)
• No debt
• Net burn: ~ $23 million
• 165 employees (16 PhD, 4 MD)
• IP Ownership: over 40 granted patents and ~150 pending
applications
Financial Overview
Proprietary data of Pluristem Therapeutics Inc.
5
PLX Technology
Proprietary data of Pluristem Therapeutics Inc.
6
Selected for EU Adaptive Pathways –
potential for marketing approval in
2018
Proprietary data of Pluristem Therapeutics Inc.
7
Partner Indication Deal structure
Pulmonary Arterial Hypertension (PAH)
Worldwide license
Licensing - (upfront payment of $7M, additional $48M in milestones, cells supply (cost +) and royalties in gross margin
IC, CLI South Korea only
JV following marketing authorization of the Korean authorities
Acute Radiation Syndrome U.S. National Institutes of Health to Support Development of Pluristem's PLX-R18
Pluristem keeps IP and manufacturing rights in all collaborations
Collaborations
Proprietary data of Pluristem Therapeutics Inc.
8
Clinical Programs 8
8
Proprietary data of Pluristem Therapeutics Inc.
9
PLX-PAD
Proprietary data of Pluristem Therapeutics Inc.
10
• Two completed Phase I studies in critical limb ischemia – positive results for both the U.S. and German trials
• One ongoing Phase II study in intermittent claudication (N=150)
• Planned studies in CLI:
o Phase II/III in Europe via Adaptive Pathways pilot project Pluristem selected to Adaptive Pathways pilot project
o Phase I/II in Japan via Accelerated Pathway for Regenerative
Medicine (application submitted; cell quality and production methods already recognized by PMDA)
Completed, Ongoing and Planned Studies with PLX-PAD in Peripheral Artery Disease
Proprietary data of Pluristem Therapeutics Inc.
11
Conditional Approval vs. Traditional Pathway to Market in EU
Phase II RCT Conditional MA*
2016 2017 2018 2019 2020 2021
Collection of real-world Data from patients treated with PLX-PAD
Full MA*
Phase II RCT Two Phase III RCTs Full MA*
Conditional Aprroval
Conservative Pathway
MA = marketing authorization
Proprietary data of Pluristem Therapeutics Inc.
12
Event Rate USA data (AFS- 100%) Germany data (AFS- 73%) Average (85%) Published historical data
Summary Data from Both Phase I Studies, N=27
12 month - 85% Amputation-Free Survival (AFS)
Proprietary data of Pluristem Therapeutics Inc.
13
PLX-PAD CLI program status in Europe
• 3-4 years earlier in a multi-billion market
• Manufacturing facility approved and inspected by European
Qualified Person for Phase III and marketing
• Granted European patent for the use of PLX in ischemic
disease
• Increased probability of a large pharma deal
• EMA new approach to expand the use of PLX-PAD to
additional indications within PAD and other ischemic
conditions
Proprietary data of Pluristem Therapeutics Inc.
14
PLX PAD- Orthopedic Indication Phase II Completed
Proprietary data of Pluristem Therapeutics Inc.
15
Strong Clinical Data Muscle Injury following Total Hip Replacement N=20
Proprietary data of Pluristem Therapeutics Inc.
16
Improvement of 500%
P=0.0067
Strong Data on Efficacy in Muscle injury Following Total Hip Replacement
Proprietary data of Pluristem Therapeutics Inc.
17
Correlation Between Improvement in the Muscle Force of Injured and Contralateral Leg
Contralateral (non–operated)
-20
-15
-10
-5
0
5
10
15
20
25
30
chan
ge in
stre
nght
of c
ontr
alat
eral
leg
Placebo150M PLX-PAD300M PLX-PAD
6 12 26
150M vs. Placebo p=0.0114
Time (Week
-15-10-505
10152025303540
cha
nge
in s
tren
ght
of o
pera
ted
leg
Time (Weeks)
Placebo150M PLX-PAD300M PLX-PAD
6 12 26
150M vs. Placebo : p=0.0067
Injured (operated)
Proprietary data of Pluristem Therapeutics Inc.
18
Ongoing Clinical Trials – PLX-PAD
• Intermittent Claudication (IC): Phase II multinational, randomized, double blind, placebo controlled study. Primary End Point: Maximal Walking Distance (MWD) at 12 months compared to baseline, N=150 (as of December 31, 2014, 64 patients enrolled)
• Pulmonary Arterial hypertension (PAH): - Phase I, open
label, dose escalation study. Primary End Point: safety & efficacy at weeks 6 and 12, and at 12 months, N=9 (as of December 31, 2014, 3 patients enrolled)
Proprietary data of Pluristem Therapeutics Inc.
19
PLX R18 Hematologic Indications
Proprietary data of Pluristem Therapeutics Inc.
20
PLX-R18 Target Indications Bone marrow failure including: • Incomplete engraftment after bone marrow transplantation • Acute Radiation Syndrome (ARS) – supported by the U.S. National Institutes of
Health (NIH) • Two significant animal trials announced
o Animal Rule pathway • Aplastic Anemia (AA) – FDA Orphan Drug designation • Chemotherapy induced bone marrow failure - Pre-Clinical PoC
• Bone Marrow Transplant failure (compassionate use – human data)
Support for Hematopoietic cell Transplantation (HCT): • Umbilical cord blood transplantation – Pre-Clinical PoC • Bone Marrow Transplantation – Pre-Clinical PoC
Proprietary data of Pluristem Therapeutics Inc.
21
U.S. National Institutes of Health to Support Development of Pluristem's PLX-R18
US Government Collaboration for ARS
Proprietary data of Pluristem Therapeutics Inc.
22
• “Exploratory” Phase I/II trial in hematological indication with
PLX-R18 under new expedited approval pathway for regenerative therapy in Japan o Positive results potentially sufficient for limited marketing
authorization
• Phase I trial in hematological indication with PLX-R18 in U.S.
• Later-phase animal trials by U.S. National Institutes of Health for Acute Radiation Syndrome via Animal Rule pathway o NO human efficacy trials needed for approval o If approved, government stockpiling for ARS to be
integrated with storage for civilian use in other indications
Planned Clinical Trials
Proprietary data of Pluristem Therapeutics Inc.
23
The Process is the Product
Proprietary data of Pluristem Therapeutics Inc.
24
Allogeneic MSC “the process is the product”
Paracrine/endocrine effects leads to emphasis on the secretion profile
Proprietary 3D platform to enable controlled 3D culturing to ensure “batch-to-batch” comparability and to modify the secretion profile as needed- PLX-PAD, PLX-R18 and others.
Monolayer Vs. Multilayer • 3D Cell-Cell interaction
• PLX cells harvested following extracellular collagen-cells interaction
• High yield
Pro-angiogenic
Undetermined
Anti-angiogenic
Proprietary data of Pluristem Therapeutics Inc.
25
3D manufacturing = 150,000 doses annually
Proprietary data of Pluristem Therapeutics Inc.
26
PLX-PAD CMC Approved by 5 Regulatory Agencies
FDA, PEI (Germany), EMA, South Korean & Israeli Regulatory Agencies: • Confirmed Batch-to-Batch Comparability, Using Multiple Donors • CMC Certification for 3D culturing for Phase II, III and Marketing
Proprietary data of Pluristem Therapeutics Inc.
27
IC
CLI (Adaptive EU)
CLI (Japan)
Orthopedic indication
Hematology
ARS
PAH
Preeclampsia
End of enrollmen
t
27
Company milestones H2-2014
H1-2015
H2-2015
H1-2016
H2-2016
H1-2017
H2-2017
H1-2018
H2-2018
indication End of
enrollment
Data Readout
Licensing deal
Study initiatio
n
Adaptive
Pathway
approval
Initial approva
l
Data Reado
ut
End of enrollmen
t
Data Readou
t
Study initiatio
n
Conditional approval
We will seek to include the indication under the Adaptive licensing pathway- based on discussion with EMA
IND Study initiation
End of enrollment
Data Readout
Adaptive or phase
II/III
Pivotal study
Data Reado
ut
BLA application
UT will pursue IND upon completion of the phase I
We will seek to include preeclampsia under the Adaptive licensing pathway- based on discussion with EMA
Proprietary data of Pluristem Therapeutics Inc.
28
Zami Aberman Chairman & CEO
Efrat Livne-Hadass VP Human Resources
Racheli Ofir, Ph.D. VP Research & Intellectual Property
Sagi Moran VP Operations
Erez Egozi VP Finance Karine Kleinhaus, M.D., MPH Divisional VP, North America
Yaky Yanay President & COO
Hillit Mannor Shachar, M.D., M.B.A. VP Business Development
Ohad Karnieli, Ph.D., M.B.A. VP Technology & Manufacturing
Esther Lukasiewicz Hagai, M.D., Ph.D. VP Clinical & Medical Affairs
Orly Amiran VP Quality Assurance
Management Team
Proprietary data of Pluristem Therapeutics Inc.
29